Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy Volunteers

NCT04588428 is registered in ClinicalTrials.gov with Inovio Pharmaceuticals as lead sponsor.

NCT NCT04588428
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04588428 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy Volunteers
Lead sponsor
Inovio Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
June 21, 2021
Completion date
January 19, 2023
Enrollment
192 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

middle east respiratory syndrome coronavirus (mers-cov)